What Akeso’s AK138D1 and ivonescimab combination must prove in advanced NSCLC
Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.
Pharma & Biotech
Pharma & Biotech
Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything
Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.
Pharma & Biotech
Summit Therapeutics nears FDA decision with stronger ivonescimab survival signal
Ivonescimab’s updated HARMONi survival trend strengthens before the FDA’s November decision, but key statistical details remain undisclosed.
Pharma & Biotech
Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.
Pharma & Biotech
Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?
Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.
Pharma & Biotech
Ivonescimab delivers 80% response in TNBC: Is Akeso redefining PD-1 treatment?
Ivonescimab shows 80 percent response in TNBC Phase II study. Explore how Akeso’s bispecific strategy could reshape PD-1 therapy in first-line settings.